Patents Assigned to Zander Therapeutics, Inc.
  • Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes
    Patent number: 10716810
    Abstract: Described are compositions of matter, protocols, and treatment means for induction of immune mediated killing in dogs suffering from cancer. The invention provides means of extracting peripheral blood from a canine patient, expanding immunocytes capable of killing cancer cells in vitro, and re-administering said immunocytes into a patient in need of therapy. In one embodiment, immunocytes expanded are T cells possessing tumor cytotoxic activity induced by stimulation of NKG2D.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: July 21, 2020
    Assignee: Zander Therapeutics, Inc.
    Inventors: Thomas Ichim, David Koos
  • SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS
    Publication number: 20200071307
    Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.
    Type: Application
    Filed: November 12, 2019
    Publication date: March 5, 2020
    Applicant: ZANDER THERAPEUTICS, INC.
    Inventors: Harry M. Lander, David R. Koos
  • Small molecule agonists and antagonists of NR2F6 activity in animals
    Patent number: 10472351
    Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: November 12, 2019
    Assignee: Zander Therapeutics, Inc.
    Inventors: Harry M. Lander, David R. Koos
  • CANINE AUTOLOGOUS IMMUNOTHERAPY USING DENDRITIC CELL INDUCED CANCER KILLING IMMUNOCYTES
    Publication number: 20190000879
    Abstract: Described are compositions of matter, protocols, and treatment means for induction of immune mediated killing in dogs suffering from cancer. The invention provides means of extracting peripheral blood from a canine patient, expanding immunocytes capable of killing cancer cells in vitro, and re-administering said immunocytes into a patient in need of therapy. In one embodiment, immunocytes expanded are T cells possessing tumor cytotoxic activity induced by stimulation of NKG2D.
    Type: Application
    Filed: July 24, 2018
    Publication date: January 3, 2019
    Applicant: Zander Therapeutics, Inc.
    Inventors: Thomas Ichim, David Koos